VERV Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.18%, SMA50 35.51%, SMA200 72.51%). The stock’s 14-day RSI is 76.26 (overbought), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.41% below its high and over 288.52% above its low.

Verve Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.37. This means the shares are trading below this model’s fair value.

Verve Therapeutics, Inc. (NASDAQ:VERV) closed at $11.13 USD, gaining $0.03 (0.27%) from the previous close of $11.10. The stock is currently within 5% of its 52-week high $2.87 and $11.40. With a market capitalization of about $994.04 million, Verve Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.24). Key stats such as the average daily volume over the past year has been around 5.72 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Verve Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sekar Kathiresan, the company employs approximately 274 people and listed since June 17, 2021. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.

Verve Therapeutics, Inc. generated EPS of -$2.11 over the past year. Five-year average earnings growth is -42.43%. The latest quarter delivered EPS of -$0.59. The next quarter is forecast at -$0.65. Next year's EPS is expected at -$5.33. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $11.00. The high target offers 34.77% upside. The low target suggests -1.17% downside. The mean target is $13.50. This offers 21.29% upside. Verve Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 14, 2025, missed forecasts by -15.71%. The prior quarter beat by -50.7%. Over the last six quarters, Apple has recorded several small beats. These include -13.24% in May 08, 2024.

Verve Therapeutics, Inc. has 89.31 million shares outstanding. The public float is 65.37 million shares, elevated short interest at 13.11% of float. This equals 9.89 million shares. The short ratio is 1.25 days. Institutional investors hold 99.78% of the float. Insiders own 5.1%. Redmile Group, LLC holds 1.94 million shares, Yeshwant Krishna has 1.80 million shares and Cormorant Asset Management, LP has 984.22 thousand shares.

Verve Therapeutics, Inc. trades at a P/E ratio of -7.53, slightly below the S&P 500 average, with a price-to-sales ratio of 18.78 and a price-to-book ratio of 2.09 suggesting the stock is closer to book value. The P/FCF stands at -8.89, also below market averages.

Verve Therapeutics, Inc. (NASDAQ:VERV) shares are up 97.34% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Verve Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.53. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $30.36, suggesting 172.78% upside. Our AI forecast model points to short-term strength (14.02% over two weeks), a medium-term fall (-69.9% over three months), and a longer-term gain (149.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Verve Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.02%, with price expected at $12.69 by August 07, 2025, within a range of $10.83 to $14.53 3-Month Outlook: Projected fall of -69.9%, reaching $3.35 by October 22, 2025, with a range of $2.27 to $3.70. 1-Year Outlook: Projected gain of 149.6%, with price at $27.78 by July 24, 2026, within a range of $8.91 to $43.77.